

Review Article Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery

Monali S. Malvankar-Mehta^(b),^{1,2} Angel Fu,³ Yasoda Subramanian,⁴ and Cindy Hutnik¹

¹Department of Ophthalmology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada

²Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada

³Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada ⁴Royal College of Surgeons in Ireland, Dublin, Ireland

Correspondence should be addressed to Monali S. Malvankar-Mehta; monali.malvankar@sjhc.london.on.ca

Received 5 December 2019; Accepted 27 February 2020; Published 20 October 2020

Academic Editor: Van C. Lansingh

Copyright © 2020 Monali S. Malvankar-Mehta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Ophthalmic viscoelastic devices (OVDs) used during small-incision cataract surgery have numerous advantages. However, OVDs have longer retention time in an eye after surgery resulting in intraocular pressure (IOP) spikes. The purpose of this study is to analyze and quantify the effect of various OVDs on both IOP and best corrected visual acuity (BCVA) by systematically reviewing the literature and performing meta-analysis. *Methods*. Numerous databases from January 1, 1985, to present were systematically searched. Thirty-six (3893 subjects) of 3313 studies identified were included for analysis. Standardized mean difference (SMD) was computed, and meta-analysis was performed. *Results*. A total of 3313 records were retrieved including 1114 from database search and 2199 from grey literature search. Significant increase in postoperative IOP in 1-day follow-up with Healon (SMD = 0.37, CI: [0.07, 0.67]), Viscoat (SMD = 0.29, CI: [0.13, 0.45]), Provisc (SMD = 0.46, CI: [0.17, 0.76]), and Soft Shell (SMD = 0.58, CI: [0.30, 0.86]) was computed. On the other hand, results implied a nonsignificant increase in postoperative IOP with Healon GV (SMD = 0.07, CI: [-0.28, 0.41]), Healon5 (SMD = 0.15, CI: [-0.33, 0.64]), 2% HPMC (SMD = 0.32, CI: [-0.0, 0.64]), and OcuCoat (SMD = 0.26, CI: [-0.37, 0.9]). Additionally, a nonsignificant reduction in postoperative IOP was inferred with Viscoat + Provisc (SMD = -0.28, CI: [-2.23, 1.68]). *Conclusion*. Improvement in IOP was shown with Viscoat + Provisc. Additionally, IOP nonsignificant upsurge was observed with Healon GV, Healon5, 2% HPMC, and OcuCoat compared to significant upsurge with Healon, Viscoat, and Soft Shell.

1. Introduction

A small-incision cataract surgery is the preferred method of cataract surgery by most surgeons. Ophthalmic viscoelastic devices (OVDs) have numerous advantages during smallincision cataract surgery. OVDs protect corneal endothelium against fluid turbulence, oxygen free radicals released during ultrasound [1], contact with surgical instruments, air bubbles, and lens fragmentation [2]; facilitate surgical procedure; reduce the risk of collateral damage to delicate intraocular tissues [3], maintain the anterior chamber space and stability to avoid capsular rupture [3]; and provide clarity to avoid complications. These properties may vary based on physical, chemical, and rheological characteristics of OVDs [4]. An ideal OVD [5]—which does not exist yet—would be easy to inject into the eye, would maintain anterior chamber [6], would not impair vision by trapping air bubbles, would not increase intraocular pressure (IOP), and would be easy to remove from the eye after the surgery.




FIGURE 1: PRISMA 2009 flow diagram (from [15]; for more information, visit http://www.prisma-statement.org).

However, a major disadvantage of OVDs is longer retention time in an eye after cataract surgery resulting in IOP spikes [7–10]. OVDs remain in the eye resulting in mechanical obstruction of the trabecular meshwork, impeding outflow and causing IOP spikes within 24 hours after surgery which have become a concern [10], specifically for glaucoma patients. In glaucoma patients, IOP spikes may cause significant damage to the optic disc [9].

In the literature, numerous prospective randomized control trials (RCTs) have been conducted to compare safety, efficacy, and performance of various OVDs used during routine small-incision cataract surgeries and intraocular lens (IOL) implantation. Most studies compared preoperative characteristics including best corrected visual acuity (BCVA), central corneal thickness (CCT), endothelial cell count (ECC), and IOP with postoperative characteristics in various OVDs at several time intervals. Few studies suggested that super viscous and cohesive OVDs take longer time to remove from a normal eye leading to IOP elevation for a greater time period [3, 4, 11, 12]. On the other hand, few studies state that longer aspiration time is required to remove dispersive OVDs [1] compared to cohesive OVDs [1, 10, 13].

In 2009, a single study [14] evaluated the protective effect of different viscoadaptive, super viscosity cohesive, viscous cohesive, medium viscosity dispersive, very low viscosity dispersive, and Soft Shell devices on ECC during cataract surgery by conducting a meta-analysis. Our research expands by evaluating the effect of various OVDs on IOP and BCVA during small-incision cataract surgery by performing a systematic review and meta-analysis. For systematic review, published as well as unpublished (grey) literature is systematically searched and data is synthesized from the included articles to compare various OVDs in order to investigate the answer to two key questions: (1) Which OVD causes the greatest risk of an IOP spike? (2) What is the specific postoperative time point at which an IOP spike is most likely to occur?

2. Methods

2.1. Search Strategy. In this work, we adhered to the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15]. Bibliographic databases, including MEDLINE (OVID and PubMed), EMBASE (OVID), BIOSIS Previews (Thomson-Reuters), CINAHL (EBSCO), Health Economic Evaluations Database (HEED), ISI Web of Science (Thomson-

Author (year)	Study design	Study location	OVDs	N (eyes)	Mean age	Age (SD)
Arshinoff (1997) [11]	RCT	Canada	MicroVisc	51	70	10
	RCT	Canada	Healon	49	70	11
Arshinoff (1998) [4]	RCT	Canada	MicroVisc Plus	100	70	10
Arshinon (1998) [4]	RCT	Canada	Healon GV	100	66	10
	RCT	Canada	Healon5	50	71.5	9.6
Arshinoff (2002) [3]	RCT	Canada	Healon GV	99	71.7	9.6
	RCT	Canada	Healon	49	71.9	7.5
Auffarth (2017) [18]	RCT	Europe	Twinvisc	109	71.9	7.4
	RCT	Europe	DuoVisc	111	72.5	7.9
	RCT	Sweden	Healon GV	21	72	10.4
Behndig (2002) [19]	RCT	Sweden	Viscoat + Healon GV	20	72.8	11.7
	RCT	Sweden	Viscoat + Provisc	21	76.5	8.4
Chiselita (2008) [20]	RCT	Romania	Viscoat	44	68.8	9.8
Sincenta (2000) [20]	RCT	Romania	Provisc	52	68.8	9.8
	RCT	USA	Amvisc Plus	17	_	_
Davis (2000) [2]	RCT	USA	OcuCoat	17	_	—
	RCT	USA	Viscoat	16	_	_
Embriano (1989) [21]	RCT	USA	Sodium chondroitin sulfate-NaHa	50	—	—
	RCT	USA	NaHa	50	_	_
Equip dala (2012) [22]	RCT	Brazil	DisCoVisc	39	71.5	7.9
Espindola (2012) [22]	RCT	Brazil	2% HPMC	39	71.5	7.9
	RCT	Germany	Healon GV	12	71.2	7.8
	RCT	Germany	Healon5	19	71.2	7.8
Holzer (2001) [1]	RCT	Germany	Viscoat	20	71.2	7.8
	RCT	Germany	OcuCoat	15	71.2	7.8
	RCT	Germany	Celoftal	15	71.2	7.8
	RCT	Germany	Methocel	50	_	
	RCT	Germany	Viscoat	50	—	_
Hutz (1996) [23]	RCT	Germany	Healon	50	_	_
	RCT	Germany	Healon GV	50	_	_
	RCT	Korea	Soft Shell (Viscoat + Hyal-2000)	69	64.15	12.92
K_{im} (2004) [24]	RCT	Korea	Viscoat	64	67.53	10.19
Kim (2004) [24]	RCT	Korea	Hyal-2000	64	63.22	11.51
	RCT	Korea	Provisc	55	63.3	12.78
Kasak Altintas (2006) [25]	RCT	Turkey	BD Visc	83	65.6	11.1
Kocak-Altintas (2006) [25]	RCT	Turkey	Healon	83	65.8	11.3
	RCT	Germany	Healon	30	73.2	9.2
Kohnen (1996) [12]	RCT	Germany	Healon GV	30	73.2	9.2
	RCT	Korea	Amvisc Plus	31	65.42	12.20
Lee (2011) [26]	RCT	Korea	Balanced salt solution + Amvisc Plus	31	63.23	9.44
	RCT	USA	Healon GV	70	75.8	6.79
Miller (1999) [5]	RCT	USA	Viscoat	70	75.5	6.38
	RCT	Japan	Opegan	50	75.6	8.0
Miyata (2002a) [27]	RCT	Japan	Healon	28	74.3	8.7
	RCT		Soft Shell	37	74.8	10.2
Miyata (2002b) [28]	RCT	Japan Japan	Healon	23	74.8 76.5	8.5
		· 1				
Moschos (2011) [13]	RCT	Greece	Viscoat Visthesia	41	77.6	8.4
	RCT	Greece		36	77.7	8.7
Neumayer (2008) [29]	RCT	UK	Neocrom Cohesive	29	75	_
	RCT	UK	Healon	29	75	_
Oshika (2004) [30]	RCT	Japan	Healon5	79	69	10
(/[00]	RCT	Japan	Healon	78	71	9
Oshika (2010) [6]	RCT	Japan	DisCoVisc	157	70.3	8.2
Commu (2010) [0]	RCT	Japan	Healon5	166	70.3	7.9
Pau Chaudham (2005) [21]	RCT	UK	Ophthalin	51	_	_
Ray-Chaudhary (2005) [31]	RCT	UK	HPMC-Ophtal	50	_	_
			-			0.1
Rainer (2000) [7]	RCT	Austria	Healon5	35	75.5	9.1

TABLE 1: Characteristics of studies included in meta-analysis.

Author (year)	Study design	Study location	OVDs	N (eyes)	Mean age	Age (SD)
Rainer (2001) [8]	RCT	Austria	OcuCoat	40	75.9	9.3
Kallel (2001) [8]	RCT	Austria	Viscoat	40	75.9	9.3
D_{aiman} (2007) [10]	RCT	Austria	NaHa 1%	40	75.1	8.0
Rainer (2007) [10]	RCT	Austria	2% HPMC	40	75.1	8.0
Rainer (2008) [32]	RCT	Austria	Viscoat	30	76.6	7.4
Kaller (2008) [52]	RCT	Austria	DuoVisc	30	76.6	7.4
	RCT	Italy	Healon	16	64.06	5.97
Ravalico (1997) [33]	RCT	Italy	Healon GV	15	61.64	9.56
Ravalico (1997) [55]	RCT	Italy	Viscoat	14	62.67	6.34
	RCT	Italy	Hymecel	13	62.85	7.55
Schwann (2000) [24]	RCT	Germany	Healon5	20	_	_
Schwenn (2000) [34]	RCT	Germany	Viscoat	28	—	
Stankovic (2008) [35]	RCT	Serbia	2% HPMC	20	_	_
Stanković (2008) [55]	RCT	Serbia	Chondroitin sulfate 4%- NaHa 3%	20	—	
	RCT	Denmark	Celoftal	17	77.9	8.1
Storr-Paulsen (2007) [36]	RCT	Denmark	Vitrax	16	76.6	10.4
	RCT	Denmark	Healon	19	76.4	13.1
Strobel (1997) [37]	RCT	Germany	Healon GV	30	68.9	10.8
Strober (1997) [37]	RCT	Germany	Healon	30	73.6	10.2
Thirumalai (2007) [38]	RCT	UK	Healon GV	415	_	_
	RCT	India	Viscoat	19	69.6	9.2
Vajpayee (2005) [39]	RCT	India	Healon GV	19	65.8	7.8
	RCT	India	Healon5	18	70.8	9.9
Vh	RCT	Japan	Opegan	34	68.6	8.2
Yachimori (2004) [40]	RCT	Japan	Soft Shell	35	70.7	8.3


TABLE 1: Continued.


TABLE 2: Reported wash-out times for OVDs.


A	OVD-	Ν	Wash-out time for OVD (seconds)
Author (year)	OVDs	(eyes)	Mean [SD]
Espindola	DisCoVisc	39	10.2 [3.6]
(2012)	2% HPMC	39	13.2 [5.4]
	Methocel	50	Healon was the easiest and quickest to remove from the anterior chamber. Healon
	Viscoat	50	GV was also removed easily in a short time; however, in two patients very small
Hutz (1996)	Healon	50	particles of the iris pigment were mobilized by the Healon GV. Visco adhered to
	Healon GV	50	the intraocular structures and was difficult to remove from the eye; Methocel was difficult to remove from the corneal endothelium
	Soft Shell (Viscoat + Hyal- 2000)	69	Soft Shell technique enhances OVD removal at the conclusion of surgery
Kim (2004)	Viscoat	64	_
	Hyal-2000	64	_
	Provisc	55	_
Kohnen	Healon	30	No difference between the two groups with 20-second and 40-second wash-out
(1996)	Healon GV	30	times
	Amvisc Plus	31	50.42 [3.83]
Lee (2011)	Balanced salt Solution + Amvisc Plus	31	8.29 [4.40]
Miller (1999)	Healon GV	70	19.8 [22.2]
Miller (1999)	Viscoat	70	75 [16.8]
Oshika (2004)	Healon5	78	Usalan was significantly assign to remove compared to Usalan
Osliika (2004)	Healon	79	Healon was significantly easier to remove compared to Healon5
Oshika (2010)	DisCoVisc	154	DisCoVisc showed significantly better performance than Healon5 in terms of
Osliika (2010)	Healon5	163	removal
Rainer (2007)	NaHa 1%	40	Removal of NaHa 1% was easy and faster than 2% HPMC in bulk fashion
Kalliel (2007)	2% HPMC	40	Removal of Ivalia 1% was easy and laster than 2% firmer. In burk lashion
Vainavee	Viscoat	19	66.6 [11.2]
Vajpayee (2005)	Healon GV	19	45.1 [9.0]
(2003)	Healon5	18	55.47 [6.6]

Author (year)	OVDs	N (eyes)	Adverse events (rates in %)
Auffarth (2017)	Twinvisc	109	Ocular hypertension (12.6%), corneal edema (0.9%), cystoid macular edema (0.9%); IOP ≥ 30 mmHg in 6 hours postop (6.5%), 24 hours (0.9%), 7 days (0.9%), 30 days (0%), 90 days (0%)
	DuoVisc	111	Ocular hypertension (17.6%), corneal edema (0.9%), inflammation (0.9%), capsule break (0.9%), bubbles in Viscoat OVD (0.9%); IOP \ge 30 mmHg in 6 hours postop (7.2%), 24 hours (0%), 7 days (0%), 30 days (0%), 90 days (0%)
Espindola (2012)	DisCoVisc 2% HPMC	39 39	No intraoperative and postoperative complications
Hutz (1996)	Methocel Viscoat Healon Healon GV	50 50 50 50	Pressure peaks up to 44 mm·Hg requiring acetazolamide (Diamox) treatment occurred twice in the Healon GV group and once in the Healon group postoperatively. Peaks up to 38 mm·Hg occurred three times in the Viscoat group, and peaks up to 35 mm Hg occurred six times in the Methocel group
Oshika (2004)	Healon5 Healon	78 79	IOP elevation (5.1%), corneal edema (2.5%), nausea and vomiting (1.3%) IOP elevation (1.3%), corneal edema (1.3%)
Oshika (2010)	DisCoVisc Healon5	154 163	$IOP \ge 30 \text{ mmHg in 5 h postop (7.2\%)}$ $IOP \ge 30 \text{ mmHg in 5 h postop (7.4\%), mild corneal edema (0.6\%), macular edema (0.6\%)}$
Ray-Chaudhary (2006)	Ophthalin HPMC- Ophtal	51 52	No significant difference in the number of complications between the two groups
D.:	NaHa 1%	40	$IOP \ge 30 \text{ mmHg in } 30 mins postop (3\%), 1 hour postop (5\%), 2 hours postop (3\%), 3 hours postop (5\%), 4 hours postop (8\%), 6 hours postop (13\%), 8 hours postop (8\%), 20–24 hours postop (0\%)$
Rainer (2007)	2% HPMC	40	$IOP \ge 30 \text{ mmHg in } 30 \text{ mins postop } (8\%), 1 \text{ hour postop } (13\%), 2 \text{ hours postop } (23\%), 3 \text{ hours postop } (13\%), 4 \text{ hours postop } (8\%), 6 \text{ hours postop } (10\%), 8 \text{ hours postop } (10\%), 20-24 \text{ hours postop } (0\%)$
Thirumalai (2007)	Healon GV	415	In 2 hours follow-up: IOP \ge 30 mmHg (7.2%), IOP \ge 35 mmHg (4%). In 24-hour follow-up: IOP \ge 30 mmHg (8.8%), IOP \ge 35 mmHg (4%). In 2-day follow-up: IOP \ge 30 mmHg (7%), IOP \ge 35 mmHg (3.5%)

TABLE 3: Complication rates reported for OVDs.









Reuters), and the Cochrane Library (Wiley) till December 2018, were searched. Database specific subject headings and key words for "ophthalmic viscoelastic device" or "ophthalmic viscosurgical device," and "increased IOP" or "endothelial cell loss" were employed in the search strategy. The searches were modified to accommodate syntax of each database (S2). OVID AutoAlerts were set up to send monthly updates with any new literature. For grey literature, various conference abstracts including the Canadian Ophthalmology Society (COS) meeting, American Academy of Ophthalmology (AAO) annual meeting, European Society of Ophthalmology (SOE), and the Association for Research in Vision and Ophthalmology (ARVO) annual meeting were searched. Additionally, Pro-Quest Dissertations and Theses database and the Canadian Health Research Collection (Ebrary) were searched.

Author r	Year of oublicatio	n OVD			SMD (95% CI)	% weight
Aution	Judificatio				31viD (93% CI)	(I - V)
30 minutes follow	-up					
Rainer	2007	Viscoat		•	1.82 (1.29, 2.34)	26.58
Rainer	2007	2% HPMC			0.66 (0.21, 1.11)	35.81
Rainer	2007	NaHa 1%		•	0.21 (-0.23, 0.65)	37.61
I-V subtotal (I-squ	ared = 90	0.8%, p = 0.000)		\diamond	0.80 (0.53, 1.07)	100.00
D + L subtotal				\bigcirc	0.89 (-0.01, 1.78)	
One hour follow-u	ıp					
Chiselita	2008	Viscoat + Provi	sc		0.76 (0.36, 1.16)	13.07
Chiselita	2008	Viscoat			1.50 (1.03, 1.97)	9.40
Chiselita	2008	Provisc			0.98 (0.57, 1.39)	12.74
Rainer	2007	Viscoat		\rightarrow	2.04 (1.50, 2.58)	7.18
Rainer	2008	Viscoat			1.74 (1.14, 2.33)	5.94
Rainer	2007	2% HPMC			1.07 (0.60, 1.53)	9.60
Rainer	2007	NaHa 1%			0.50 (0.05, 0.94)	10.66
Rainer	2008	DuoVisc			1.16 (0.61, 1.70)	7.04
Ray-Chaudhary	2006	Ophthalin			1.13 (0.71, 1.55)	12.07
Ray-Chaudhary	2006	HPMC - Opht	վ		0.96 (0.55, 1.38)	12.30
I - V subtotal (I-sc	juared = 6	-		\diamond	1.11 (0.96, 1.25)	100.00
D + L subtotal	-	*		\diamond	1.16 (0.89, 1.42)	
			-2.58	0 2.5		

FIGURE 4: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by 30-minute and one-hour follow-up.

Author	Year of publication	n OVD			SMD (95% CI)	% weight (I - V)
Five hours fol	low-up					
Behndig	2002	Healon GV	-+	<u> </u>	0.00 (-0.60, 0.60)	6.21
Arshinoff	2002	Healon 5			0.61 (0.21, 1.01)	14.13
Arshinoff	2002	Healon GV vs Healon 5		+	0.65 (0.37, 0.94)	27.81
Behndig	2002	Viscoat + Healon GV		_	-0.26 (-0.88, 0.37)	5.87
Behndig	2002	Viscoat + Provisc		-	-0.46 (-1.07, 0.16)	6.05
Espindola	2012	DisCoVisc	+	•	0.30 (-0.15, 0.74)	11.41
Espindola	2012	2% HPMC	+	•	0.29 (-0.15, 0.74)	11.42
Yachimori	2004	Soft Shell		\rightarrow	1.42 (0.90, 1.95)	8.22
Yachimori	2004	Opegan			1.01 (0.51, 1.52)	8.88
I - V subtotal	(I-squared =	78.0%, <i>p</i> = 0.000)		\diamond	0.50 (0.35, 0.65)	100.00
D + L subtota	1			\diamond	0.42 (0.09, 0.76)	
		-1.9	5 0	1.95		

FIGURE 5: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by five-hour follow-up.

2.2. Selection Criteria. Randomized controlled trials, published in English language, discussing unilateral and bilateral cataract surgery on human subjects above the age of 19 and older were included. No restriction was placed based on study location. Figure 1 summarizes the PRISMA flow diagram.

In total, 1114 records were retrieved from multiple databases including MEDLINE (213), EMBASE (639), ISI Web of Science (195) Cochrane Library (5), and CINAHL (62). An additional 2,199 records were identified through grey literature searches. EPPI-Reviewer 4 gateway (by EPPI-Centre, Social Science Research Unit, the Institute of Education, University of London, UK) was used to conduct the systematic review. All identified records were imported to EPPI-Reviewer 4 to remove duplicates. After removing duplicates (217 records), 3,096 records were included for the three-level screening process.

Year of		% weight
Author publication	SMD (95% CI)	(I - V)
Healon		
Arshinoff 1997 -	-0.57 (-0.97, -0.16)	25.92
Hutz 1996	0.50 (0.10, 0.90)	26.68
Kohen 1996	0.70 (0.18, 1.23)	15.53
Neumayer 2008	0.53 (0.00, 1.05)	15.42
Strobel 1997	0.18 (-0.33, 0.69)	16.45
I - V subtotal (I -squared = 81.0%, p = 0.000)	0.21 (0.00, 0.41)	100.00
D + L subtotal	0.26 (-0.22, 0.73)	
Healon GV		
Arshinoff 1998 +	0.17 (-0.11, 0.45)	46.16
Holzer 2001	1.42 (0.52, 2.32)	4.36
Hutz 1996	0.61 (0.21, 1.01)	22.10
Kohen 1996	0.49(-0.03, 1.00)	13.49
Strobel 1997	0.07 (-0.43, 0.58)	13.89
I - V subtotal (I -squared = 60.1%, p = 0.040)	0.35 (0.16, 0.54)	100.00
D + L subtotal	0.44 (0.11, 0.77)	
Healon 5		
Holzer 2001	- 1.94 (1.16, 2.71)	29.57
Rainer 2000	1.10 (0.60, 1.60)	70.43
<i>I</i> - <i>V</i> subtotal (<i>I</i> -squared = 68.1% , <i>p</i> = 0.077)	1.35 (0.92, 1.77)	100.00
D + L subtotal	1.46 (0.65, 2.28)	
Viscoat		
Chiselita 2008	1.42 (0.95, 1.89)	16.82
Holzer 2001	1.44 (0.74, 2.13)	7.56
Hutz 1996 -	0.41 (0.02, 0.81)	23.52
Rainer 2000	1.50 (0.96, 2.03)	13.06
Rainer 2001	1.33 (0.85, 1.82)	15.67
Rainer 2007	1.86 (1.34, 2.39)	13.30
Rainer 2008	1.83 (1.22, 2.44)	10.06
I - V subtotal (I -squared = 78.2%, p = 0.000)	1.28 (1.09, 1.47)	100.00
D + L subtotal	1.38 (0.96, 1.80)	
2% HPMC		
Rainer 2007	1.29 (0.81, 1.77)	65.00
Stankovic 2008	0.98 (0.32, 1.64)	35.00
I - V subtotal (I -squared = 0.0%, p = 0.458)	1.18 (0.79, 1.57)	100.00
$D + L$ subtotal \diamondsuit	1.18 (0.79, 1.57)	
OcuCoat		
Holzer 2001	0.94 (0.19, 1.70)	27.26
Rainer 2001	0.96 (0.50, 1.42)	72.74
I - V subtotal (I squared = 0.0%, p = 0.967)	0.96 (0.56, 1.35)	100.00
$D + L$ subtotal \diamondsuit	0.96 (0.56, 1.35)	
	1	
-2.71 0 2.	.71	

FIGURE 6: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by six-hour follow-up and ophthalmic viscoelastic devices (OVDs).

2.3. Screening. Tittle (Level 1) screening involved reviewing titles, while abstract (Level 2) screening involved reviewing abstracts, and full-text (Level 3) screening (S3) involved full-text reviews of included articles, independently by two reviewers (AF and YS). At each level, agreement and disagreement between the two reviewers were assessed by Cohen's kappa (κ) coefficient. Differences between the reviewers were discussed and resolved by consensus. In cases where consensus was not achieved, a third reviewer (MM) intervened to provide a decision.

2.4. Data Extraction. Data was extracted from the 36 eligible articles using a data extraction form. Data included study design, location, total patients enrolled, total patients enrolled in and completed the study, number of females, patient demographic characteristics, follow-ups, and baseline and postoperative characteristics including IOP, BCVA, CCT, and ECC. For missing data, various pieces of available information (such as the range, *p* value, and confidence interval) were utilized and converted to the common effect measure—SD. Quality of each included article was checked using modified Downs and Black checklist [16].

2.5. *Meta-Analysis*. Meta-analysis was conducted using STATA v. 15.0. (STATA Corporation, College Station, TX). By statistically combining the pre- and postoperative IOP and BCVA from included studies, the power of the analysis significantly increased, resulting in a single summary effect estimate of IOP and BCVA.

	Year of						% weight
Author	publication	OVD				SMD (95% CI)	(I - V)
Eight hours	s follow-up						
Schwenn	2000	Healon 5		•		0.76 (0.11, 1.40)	10.97
Rainer	2007	Viscoat		-		1.59 (1.09, 2.10)	17.81
Schwenn	2000	Viscoat		+		1.33 (0.75, 1.91)	13.42
Embriano	1989	Sodium chondroitin sulfate	- NaHa		•	4.39 (3.66, 5.12)	8.53
Embriano	1989	NaHa			-	4.70 (3.93, 5.47)	7.73
Rainer	2007	2% HPMC		•		1.12 (0.65, 1.59)	20.33
Rainer	2007	NaHa 1%		•		0.94 (0.48, 1.40)	21.20
I - V subtot	al (I-square	d = 95.6%, <i>p</i> = 0.000)		♦		1.71 (1.50, 1.92)	100.00
D + L subto	otal	-		\diamond		2.09 (1.06, 3.13)	
Nine hours	follow-up						
Chiselita	2008	Viscoat + Provisc		*		1.34 (0.91, 1.77)	33.80
Chiselita	2008	Viscoat		•		1.18 (0.73, 1.63)	30.40
Chiselita	2008	Provisc		•		1.20 (0.78, 1.61)	35.80
I - V subtot	al (I-square	d = 0.0%, p = 0.858		0		1.24 (0.99, 1.49)	100.00
D + L subto	· •			0		1.24 (0.99, 1.49)	
Sixteen hou	ırs follow-u	р					
Embriano	1989	Sodium chondroitin sulfate	- NaHa		-	5.84 (4.93, 6.74)	46.78
Embriano	1989	NaHa			-	5.38 (4.53, 6.23)	53.22
I - V subtot	al (I-square	d = 0.0%, p = 0.476)			\diamond	5.60 (4.98, 6.22)	100.00
D + L subto		· 1 /			Ò	5.60 (4.98, 6.22)	
			-6.74 (6.7		

FIGURE 7: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by eight-, nine-, and 16-hour follow-up.

Author	Year of publication	n OVD				SMD (95% CI)	% weight (I - V)
1 day follo	ow-up						
Altintas	2007	BD Visc		-		0.80 (0.48, 1.11)	25.54
Arshinoff	1997	MicroVisc	E.	•		-0.29 (-0.68, 0.10)	16.77
Arshinoff	1998	MicroVisc Plus		*		0.25 (-0.03, 0.53)	32.32
Embriano	1989	Sodium chondroitin sulfate - Na	Ha			5.23 (4.40, 6.06)	3.70
Embriano	1989	NaHa				4.84 (4.06, 5.62)	4.17
Espindola	2012	DisCoVisc		↓ ◆		0.03 (-0.41, 0.48)	12.96
Holzer	2001	Celoftal				0.86 (0.11, 1.61)	4.53
I - V subto	otal (I-square	ed = 97.7%, <i>p</i> = 0.000)		0		0.67 (0.51, 0.83)	100.00
D + L subt	total			\diamond		1.62 (0.50, 2.75)	
		-6.0	6	0	6.0)6	

FIGURE 8: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by 24-hour follow-up and ophthalmic viscoelastic devices (OVDs).

Standardized mean difference (SMD) was computed as the effect size. The extracted mean and standard error of the IOP at baseline and end point were used to compute the mean IOP reduction (IOPR), percentage of IOP reduction (IOPR%), and standard deviation percentage of IOP reduction (SD_{IOPR%}) [17].

SMD was calculated as the treatment effect since it is a mean difference standardized across all studies. Weights were assigned to each SMD according to the inverse of its variance, and then average was computed. SMD for each study was then aggregated using the fixed or random-effect model based on the presence of heterogeneity to estimate the summary effect.

To test heterogeneity, I^2 statistics, Z-value, and χ^2 statistics were computed. Additionally, a high Z-value, a low p value (<0.01), and a large χ^2 value imply significant heterogeneity and, therefore, a random-effects model using DerSimonian and Laird methods was computed. Funnel plots were generated to check publication bias.

Subgroup analysis was conducted to ascertain the influence of OVD following the cataract surgery on

Author	Year of publication		SMD (95% CI)	% weight (I - V)
Healon				
Altintas	2007	-	0.37 (0.07, 0.68)	31.38
Arshinoff	1997		0.00(-0.40, 0.40)	18.85
Arshinoff	2002	•	- 0.78 (0.37, 1.19)	17.50
Kohen	1996		• 0.94 (0.41, 1.48)	10.36
Miyata	2002a	•	0.10 (-0.42, 0.63)	10.76
Neumayer	2008	-	0.03 (-0.48, 0.55)	11.16
I - V subtot	al (<i>I</i> -squared = 64.7%, <i>p</i> = 0.015)	\diamond	0.37 (0.19, 0.54)	100.00
D + L subto	otal	\diamond	0.37 (0.07, 0.67)	
Healon GV				
Arshinoff	1998	-	0.00 (-0.28, 0.28)	55.12
Behndig	2002 -	•	-0.07 (-0.67, 0.54)	11.80
Holzer	2001		- 0.18 (-0.62, 0.99)	6.72
Kohen	1996	•	- 0.65 (0.13, 1.17)	15.99
Vajpayee	2005	•	-0.49 (-1.14, 0.16)	10.36
I - V subtot	al (<i>I</i> -squared = 51.4%, <i>p</i> = 0.083)	\diamond	0.06 (-0.15, 0.27)	100.00
D + L subto	otal	\Leftrightarrow	0.07 (-0.28, 0.41)	
Healon 5				
Arshinoff	2002		0.84 (0.43, 1.25)	33.51
Holzer	2001	•	- 0.35 (-0.30, 0.99)	13.68
Rainer	2000		0.12 (-0.35, 0.59)	25.54
Schwenn	2000 —	•	-0.48 (-1.11, 0.15)	14.20
Vajpayee	2005 —	•	-0.22 (-0.88, 0.43)	13.08
I - V subtot	al (<i>I</i> -squared = 74.3%, <i>p</i> = 0.004)	\diamond	0.26 (0.03, 0.50)	100.00
D + L subto	otal	\Leftrightarrow	0.15 (-0.33, 0.64)	
	-1.48	0	1.48	

FIGURE 9: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by 24-hour follow-up and ophthalmic viscoelastic devices (OVDs).

postoperative IOP and BCVA. Causes of heterogeneity were also explored.

3. Results

3.1. Search Results. Total of 36 RCTs were eligible for metaanalysis (Table 1). From these 36, 28 RCTs had data on IOP (S4), 13 studies had data on central corneal thickness (CCT), 16 studies had data on endothelial cell count (ECC), 9 studies reported data on best corrected visual acuity (BCVA) (Table 1), 10 studies listed wash-out times for OVDs (Table 2), and 9 studies reported the adverse events that occurred postoperatively (Table 3). In the end, a total of 36 studies (3893 subjects) were included for qualitative synthesis and 28 studies (2613 subjects) for quantitative synthesis (Figure 1).

3.2. Publication Bias. Figures 2 and 3 show the funnel plots (S4) for studies reporting preoperative and postoperative IOP and BCVA, respectively, for various OVDs. Figure 2 shows studies scattered from top to bottom right of the plot. Therefore, publication bias could not be concluded. Partially, the reason was difficulty in interpretation of funnel plot due to high heterogeneity and small effect sizes.

3.3. Main Outcomes

3.3.1. Effect on Intraocular Pressure. Figure 4 shows a forest plot of SMD of pre- and postoperative IOP by follow-up. A single study evaluating various OVDs showed a nonsignificant increase in the postoperative IOP in 30-minute follow-up (SMD = 0.89, CI: [-0.01, 1.78]). However, further research is required to make robust inferences. For studies investigating the effect of OVDs in 1-hour follow-up, significant (p = 0.001) heterogeneity between studies ($I^2 = 69.1\%$) was observed and, therefore, the random-effects model showed significant increase in IOP in 1-hour follow-up (SMD = 1.16, CI: [0.89, 1.42]).

Significant increase in postoperative IOP was observed in 2-hour, 3-hour, 4-hour, and 5-hour follow-up (SMD = 0.42, CI: [0.09, 0.76]) (Figure 5). Irrespective of the OVDs used, postoperative IOP in 4-hour follow-up does increase significantly. However, Viscoat + Healon GV and Viscoat + Provisc significantly reduce IOP in 5-hour followup (Figure 5). More studies evaluating Viscoat + Healon GV and Viscoat + Provisc are required.

Figure 6 shows a forest plot for subgroup analysis by OVDs for SMD of pre- and postoperative IOP in 6-hour follow-up in patients with cataract. Considerable heterogeneity between studies existed. Postoperative IOP

Year of Author publication	SMD (95% CI)	% weight (I - V)
Viscoat + Provisc Behndig 2002 Chiselita 2008 <i>I</i> - <i>V</i> subtotal (<i>I</i> -squared = 96.0%, <i>p</i> = 0.000) D + L Subtotal	-1.29 (-1.96, -0.62) 0.70 (0.30, 1.10) 0.18 (-0.17, 0.52) -0.28 (-2.23, 1.68)	26.42 73.58 100.00
Viscoat Chiselita 2008 Holzer 2001 Kim 2004 Rainer 2000 Rainer 2001 Rainer 2007 Rainer 2008 Schwenn 2000 Vajpayee 2005 $I - V$ subtotal (I -squared = 0.0%, p = 0.443) D + L subtotal	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} 13.50 \\ 6.20 \\ 20.22 \\ 11.12 \\ 12.67 \\ 12.36 \\ 9.40 \\ 8.90 \\ 5.63 \\ 100.00 \end{array}$
Provisc Chiselita 2008 Kim 2004 I - V subtotal (I -squared = 14.4%, p = 0.280) D + L subtotal	 ◆ 0.62 (0.23, 1.01) ◆ 0.32 (-0.06, 0.70) ◇ 0.46 (0.19, 0.73) ◇ 0.46 (0.17, 0.76) 	47.73 52.27 100.00
2% HPMC Espindola 2012 Rainer 2007 Stankovic 2008 - <i>I</i> - <i>V</i> subtotal (<i>I</i> -squared = 22.4%, <i>p</i> = 0.276) D + L subtotal	0.27 (−0.17, 0.72) 0.58 (0.13, 1.03) −0.03 (−0.65, 0.59) 0.33 (0.05, 0.61) 0.32 (−0.00, 0.64)	39.84 39.54 20.62
OcuCoat Holzer 2001 Rainer 2001 I - V subtotal (I -squared = 56.4%, p = 0.130) D + L subtotal	0.66 (-0.07, 1.40) 0.00 (-0.44, 0.44) 0.17 (-0.20, 0.55) 0.26 (-0.37, 0.90)	26.16 73.84 100.00
Soft Shell Kim 2004 Yachimori 2004 I - V subtotal (I -squared = 0.0%, p = 0.830) D + L subtotal	 ◆ 0.56 (0.22, 0.90) 0.63 (0.14, 1.11) ◇ 0.58 (0.30, 0.86) ◇ 0.58 (0.30, 0.86) 	66.57 33.43 100.00
-2.23	0 2.23	

FIGURE 10: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by 24-hour follow-up and ophthalmic viscoelastic devices (OVDs).

significantly increased in 6-hour follow-up with Healon GV (SMD = 0.44, CI: [0.11, 0.77]), Healon5 (SMD = 1.46, CI: [0.65, 2.28]), Viscoat (SMD = 1.38, CI: [0.96, 1.8]), 2% HPMC (SMD = 1.18, CI: [0.79, 1.57]), and OcuCoat (SMD = 0.96, CI: [0.56, 1.35]) compared to a nonsignificant increase with Healon (SMD = 0.26, CI: [-0.22, 0.73]). Healon GV, Healon5, Viscoat, 2% HPMC, and OcuCoat may significantly increase IOP in 6-hour follow-up compared to a nonsignificant increase with Healon. Results showed significant increase (Figure 7) in IOP in 8-hour (SMD = 2.09, CI: [1.06, 3.13]), 9-hour (SMD = 1.24, CI: [0.99, 1.49]), and 16-hour follow-up (SMD = 5.6, CI: [4.98, 6.22]).

Subgroup analysis of postoperative IOP in 1-day followup by OVDs is shown in Figures 8–10. Considerable heterogeneity between studies existed. Significant increase in postoperative IOP (Figures 8 and 9) in 1-day follow-up with Healon (SMD = 0.37, CI: [0.07, 0.67]), Viscoat (SMD = 0.29, CI: [0.13, 0.45]), Provisc (SMD = 0.46, CI: [0.17, 0.76]), and

Soft Shell (SMD = 0.58, CI: [0.30, 0.86]) was computed. On the other hand, results implied a nonsignificant increase in postoperative IOP with Healon GV (SMD = 0.07, CI: [-0.28, 0.41]), Healon5 (SMD = 0.15, CI: [-0.33, 0.64]), 2% HPMC (SMD = 0.32, CI: [-0.0, 0.64]), and OcuCoat (SMD = 0.26, CI: [-0.37, 0.9]). Further, a nonsignificant reduction in postoperative IOP was inferred with Viscoat+Provisc (SMD = -0.28, CI: [-2.23, 1.68]). Healon, Viscoat, and Soft Shell significantly increased IOP compared to a nonsignificant increase with Healon GV, Healon5, 2% HPMC, and OcuCoat, compared to a nonsignificant reduction in IOP with Viscoat + Provisc in 1-day follow-up. However, 2 studies evaluated Viscoat + Provisc indicating a need for more research. Results signified increase in postoperative IOP in 1-day follow-up with other OVDs (SMD = 1.62, CI: [0.5, 2.75]) (Figure 10).

Nonsignificant increase in postoperative IOP was observed in 2-day follow-up (SMD = 1.18, CI: [-0.14, 2.5]) and

Author	Year of publication	OVD			SMD (95% CI)	% weight (I - V)
2 days follow	-up					
Kohen	1996	Healon	•	ŀ	0.30 (-0.21, 0.81)	16.92
Kohen	1996	Healon GV			0.04 (-0.46, 0.55)	17.11
Embriano	1989	Sodium chondroitin sulfate - Nał	la		3.63 (2.99, 4.27)	10.65
Embriano	1989	NaHa			3.53 (2.90, 4.16)	11.02
Espindola	2012	DisCoVisc			-0.11 (-0.56, 0.33)	22.21
Espindola	2012	2% HPMC	•		-0.24 (-0.69, 0.20)	22.08
I - V subtotal	(I-squared = 97.4)	%, <i>p</i> = 0.000)		\diamond	0.76 (0.55, 0.96)	100.00
D + L subtota	al		<	>	1.18 (-0.14, 2.50)	
3 days follow	-up					
Kohen	1996	Healon		F	0.24 (-0.27, 0.75)	30.50
Kohen	1996	Healon GV	•		0.04 (-0.48, 0.57)	28.68
Stankovic	2008	2% HPMC	•		-0.22 (-0.84, 0.40)	20.36
Stankovic	2008 so	dium chondroitin sulphate 4%- NaHa	3%		-0.11 (-0.73, 0.51)	20.46
I - V subtotal	(I-squared = 0.0%)	p, p = 0.693)	•		0.02 (-0.26, 0.30)	100.00
D + L subtota	al	-	\$		0.02 (-0.26, 0.30)	
4 days follow	-up					
Schwenn	2000	Healon 5			-1.88 (-2.63, -1.13)	34.23
Schwenn	2000	Viscoat	-		-0.72 (-1.26, -0.17)	65.77
I - V subtotal	(I-squared = 83.5)	%, $p = 0.014$)	$\overline{\bigcirc}$		-1.11 (-1.55, -0.67)	100.00
D + L subtota		* '	$\overset{\cdot}{\diamondsuit}$		-1.27 (-2.40, -0.13)	
		-4.27	/ 0	4.2	27	

FIGURE 11: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by two-, three-, and four-day follow-up.

3-day follow-up (SMD = 0.02, CI: [-0.26, 0.3]). Conversely, significant reduction in postoperative IOP was observed with Healon5 and Viscoat in 4-day follow-up (SMD = -1.27, CI: [-2.4, -0.13]) (Figure 11). However, 3 studies evaluated 2-day follow-up, 2 studies assessed 3-day follow-up, and 1 study considered 4-day follow-up; therefore, good quality RCTs with longer follow-ups are needed to make inferences.

Meta-analysis showed nonsignificant reduction in postoperative IOP (Figure 12) in 1-week follow-up with Healon (SMD = -0.35, CI: [-0.71, 0.0]), Viscoat (SMD = -0.13, CI: [-0.4, 0.14]), 2% HPMC (SMD = 0.06, CI: [-0.3, 0.42]), and OcuCoat (SMD = -0.41, CI: [-0.98, 0.17]) compared to a significant increase in postoperative IOP in 1-week follow-up with Healon GV (SMD = -0.5, CI: [-0.89, -0.11]) and Healon5 (SMD = -0.42, CI: [-0.68, -0.17]). Thus, postoperative IOP in 1-week follow-up nonsignificantly decreases with Healon, Viscoat, 2% HPMC, and OcuCoat compared to a significant increase in IOP with Healon GV and Healon5.

Nonsignificant reduction in IOP occurred in 2-week follow-up (SMD = -0.24, CI: [-0.55, 0.08]) (Figure 13). However, significant reduction in postoperative IOP was observed in 1-month follow-up (SMD = -0.63, CI: [-0.78, -0.49]), 3-month follow-up (SMD = -0.69, CI: [-0.95, -0.43]), 6-month follow-up (SMD = -0.72, CI: [-0.87, -0.56]) (Figure 14) with various OVDs.

3.3.2. Effect on Best Corrected Visual Acuity (BCVA). Figure 15 represents a forest plot of BCVA by follow-up (days) for articles evaluating various OVDs in patients with cataract. Significant heterogeneity between studies examining follow-up of 1-day ($I^2 = 69.3\%$) was observed. Results specified significant improvement in postoperative BCVA in 1-day follow-up (SMD = -0.85, CI: [-1.16, -0.54]), 2-day follow-up (SMD = -0.81, CI: [-1.16, -0.46]), 3-day follow-up (SMD = -2.02, CI: [-2.46, -1.59]), and 14-day follow-up (SMD = -2.01, CI: [-2.4, -1.62]) irrespective of OVD used during cataract surgery. Therefore, BCVA improves within a day irrespective of the OVD utilized.

Figure 16 presents a forest plot of BCVA by follow-up (months) for articles examining various OVDs in patients with cataract. Results implied significant improvement in postoperative BCVA in 1-month (SMD = -2.51, CI: [-3.27, -1.75]), 3-month (SMD = -1.20, CI: [-1.68, -0.72]), and 6-month follow-up (SMD = -2.33, CI: [-3.43, -1.23]). Irrespective of the OVDs used, postoperative BCVA does improve significant improvement in postoperative BCVA does improve significant improvement in postoperative BCVA in 6-week follow-up (SMD = -0.33, CI: [-0.67, 0.02]) with Vitrax and Anterior Chamber Maintainer (ACM). Therefore, additional research is required.

Year of publication	SMD (95% CI)	% weight (I - V)
2002 2002a -squared = 17.0%, p = 0.272)	0.21 (-0.61, 0.18) -0.59 (-1.12, -0.05) -0.34 (-0.66, -0.03) -0.35 (-0.71, -0.00)	64.51 35.49 100.00
2002 2001 2005 -squared = 0.0%, p = 0.427)		41.82 21.62 36.56 100.00
2002 2001 2000 2005 -squared = 0.0%, p = 0.863)	$\begin{array}{rcl} & -0.39 \ (-0.79, \ 0.00) \\ & -0.38 \ (-1.02, \ 0.26) \\ & -0.58 \ (-1.06, \ -0.10) \\ & -0.25 \ (-0.90, \ 0.41) \\ & -0.42 \ (-0.68, \ -0.17) \\ & -0.42 \ (-0.68, \ -0.17) \end{array}$	41.18 15.66 28.16 14.99 100.00
2001 2000 2001 2007 2005 -squared = 28.4%, p = 0.232)	$\begin{array}{cccc} & & 0.03 & (-0.59, 0.65) \\ & & -0.63 & (-1.11, -0.15) \\ & & & -0.11 & (-0.54, 0.33) \\ & & & 0.03 & (-0.41, 0.47) \\ & & & 0.14 & (-0.50, 0.78) \\ & & & -0.14 & (-0.36, 0.09) \\ & & & -0.13 & (-0.40, 0.14) \end{array}$	13.14 21.89 26.24 26.28 12.45 100.00
2012 2007 -squared = 25.7%, <i>p</i> = 0.246)	 −0.13 (-0.57, 0.32) 0.24 (-0.20, 0.68) 0.06 (-0.25, 0.37) 0.00 (-0.30, 0.42) 	49.50 50.50 100.00
2001 2001 -squared = 46.8%, p = 0.170)	-0.79 (-1.53, -0.04) -0.18 (-0.62, 0.26) -0.34 (-0.72, 0.04) -0.41 (-0.98, 0.17)	25.80 74.20 100.00
	publication 2002 $2002a$ -squared = 17.0%, $p = 0.272$) 2002 2001 2005 -squared = 0.0%, $p = 0.427$) 2002 2001 2002 2001 2002 2001 2000 2000 2000 2000 2001 2000 2001 2007 2007 2007 2007 $squared = 28.4\%, p = 0.232$) 2012 2007 $squared = 25.7\%, p = 0.246$)	publication SMD (95% CI) 2002 2002a -squared = 17.0%, $p = 0.272$) -0.21 (-0.61, 0.18) -0.59 (-1.12, -0.05) -0.34 (-0.66, -0.03) -0.35 (-0.71, -0.00) 2002 2005 -squared = 0.0%, $p = 0.427$) -0.23 (-0.84, 0.38) -0.91 (-1.75, -0.06) -0.56 (-1.21, 0.08) -0.50 (-0.89, -0.11) -0.50 (-0.89, -0.11) 2002 2001 2005 -squared = 0.0%, $p = 0.427$) -0.39 (-0.79, 0.00) -0.50 (-0.89, -0.11) 2002 2005 -squared = 0.0%, $p = 0.863$) -0.39 (-0.79, 0.00) -0.38 (-1.02, 0.26) -0.58 (-1.06, -0.10) -0.25 (-0.90, 0.41) -0.42 (-0.68, -0.17) -0.42 (-0.68, -0.17) 2001 2005 -squared = 28.4%, $p = 0.232$) -0.33 (-0.59, 0.65) -0.63 (-1.11, -0.15) -0.11 (-0.54, 0.33) 0.03 (-0.41, 0.47) 0.14 (-0.50, 0.78) -0.13 (-0.57, 0.32) 0.24 (-0.20, 0.68) 0.06 (-0.25, 0.37) 0.00 (-0.30, 0.42) 2012 2007 -squared = 25.7%, $p = 0.246$) -0.13 (-0.57, 0.32) 0.24 (-0.20, 0.68) 0.06 (-0.25, 0.37) 0.00 (-0.30, 0.42) 201 -squared = 46.8%, $p = 0.170$) -0.79 (-1.53, -0.04) -0.18 (-0.62, 0.26) -0.34 (-0.72, 0.04)

FIGURE 12: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by one-week follow-up and ophthalmic viscoelastic devices (OVDs).

4. Discussion

A systematic review was conducted to evaluate the effect of various OVDs in patients with cataract. A total of 36 RCTs (3893 subjects) were included for qualitative synthesis and 28 RCTs (2613 subjects) for quantitative synthesis. Percentage of reduction in IOP and standardized mean difference (SMD) in IOP as well as BCVA were computed. Meta-analysis results showed significant increase in postoperative IOP up to 5-hour follow-up irrespective of OVDs used. Therefore, removal of OVD is essential to avoid the IOP spikes. Results suggested a nonsignificant increase in postoperative IOP in 6-hour follow-up with Healon compared to a significant increase with Healon GV, Healon5, Viscoat, 2% HPMC, and OcuCoat.

Additionally, postoperative IOP significantly increases with Healon, Viscoat, and Soft Shell compared to a

nonsignificant increase with Healon GV, Healon5, 2% HPMC, and OcuCoat, compared to a nonsignificant reduction with Viscoat+Provisc in 1-day follow-up. Postoperative IOP nonsignificantly decreases with Healon, Viscoat, 2% HPMC, and OcuCoat compared to a significant increase with Healon GV and Healon5 even after 1-week follow-up.

Meta-analysis results implied significant improvement in postoperative BCVA in a day regardless of OVD. However, a single study showed a nonsignificant improvement in postoperative BCVA in 6-week follow-up with Vitrax and Anterior Chamber Maintainer (ACM). Therefore, additional research is required.

The reason behind substantial between-study heterogeneity could reveal different study populations, demographics, inclusion/exclusion criteria, study location, design, OVDs used, surgeon's experience, available facilities to

Author	Year of publication	n OVD		SMD (95% CI)	% weight (I - V)
2 weeks foll	low-up				
Espindola	2012	DisCoVisc	_	-0.15 (-0.59, 0.30)	50.27
Espindola	2012	2% HPMC	_	-0.33 (-0.77, 0.12)	49.73
<i>I</i> - <i>V</i> subtotal (<i>I</i> -squared = 0.0% , <i>p</i> = 0.578)			\Diamond	-0.24 (-0.55, 0.08)	100.00
D + L subto	otal	*	Ň	-0.24 (-0.55, 0.08)	
1 month fo	llow-up				
Arshinoff	1997	Healon		-0.75 (-1.16, -0.34)	9.71
Kohen	1996	Healon		-0.08 (-0.60, 0.43)	6.16
Arshinoff	1997	MicroVisc		-0.82 (-1.22, -0.41)	10.00
Arshinoff	1998	MicroVisc Plus		-0.73 (-1.02, -0.44)	19.54
Arshinoff	1998	Healon GV	-	-0.77 (-1.06, -0.48)	19.39
Holzer	2001	Healon GV		-1.06 (-1.92, -0.20)	2.21
Kohen	1996	Healon GV	_	-0.04 (-0.57, 0.49)	5.74
Holzer	2001	Healon 5		-0.58 (-1.23, 0.07)	3.87
Holzer	2001	Viscoat		-0.43 (-1.06, 0.19)	4.15
Holzer	2001	OcuCoat		-0.91 (-1.67, -0.16)	2.87
Holzer	2001	Celoftal		-0.95 (-1.71, -0.19)	2.85
Shingleton	2001	Vitrax		-0.52 (-1.01, -0.03)	6.78
Shingleton	2001 A	Anterior chamber maintain	er 🔶	-0.57 (-1.06, -0.08)	6.74
<i>I</i> - <i>V</i> subtotal (I-squared = 16.5% , <i>p</i> = 0.278)			\diamond	-0.64 (-0.77, -0.52)	100.00
D + L subto	otal		Č	-0.63 (-0.78, -0.49)	
				1	
			-1.92 0	1.92	

FIGURE 13: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by two-week and one-month follow-up.

Author	Year of publication	OVD		SMD (95% CI)	% weigh (I - V)
3 months fol	llow-up				
Behndig	2002	Healon GV		-0.26 (-0.87, 0.34)	6.94
Holzer	2001	Healon GV		-0.79 (-1.62, 0.05)	3.69
Vajpayee	2005	Healon GV		-0.62 (-1.28, 0.03)	6.03
Holzer	2001	Healon 5		-0.14(-0.78, 0.49)	6.32
Schwenn	2000	Healon 5	_ • _	-1.09 (-1.75, -0.42)	5.77
Vajpayee	2005	Healon 5		-0.26 (-0.92, 0.39)	5.95
Behndig	2002	Viscoat + Healon GV		-0.66 (-1.29, -0.02)	6.31
Behndig	2002	Viscoat + Provisc		-1.66 (-2.36, -0.95)	5.15
Holzer	2001	Viscoat		-0.28 (-0.90, 0.34)	6.60
Schwenn	2000	Viscoat		-1.25 (-1.82, -0.67)	7.78
Vajpayee	2005	Viscoat		-0.11 (-0.74, 0.53)	6.33
Espindola	2012	DisCoVisc	-	-0.36(-0.80, 0.09)	12.80
Espindola	2012	2% HPMC	•	-0.41(-0.86, 0.04)	12.74
Holzer	2001	OcuCoat		-1.36 (-2.16, -0.56)	4.01
Holzer	2001	Celoftal		-1.73 (-2.57, -0.88)	3.58
I - V subtota	l (I-squared	l = 60.3%, p = 0.001)	\diamond	-0.64(-0.80, -0.48)	100.00
D + L subtot	al	*	Ň.	-0.69 (-0.95, -0.43)	
6 months fol	llow-up				
Arshinoff	1997	Healon	•	-0.73 (-1.14, -0.32)	13.83
Arshinoff	1997	MicroVisc	•	-0.78 (-1.19, -0.38)	14.25
Arshinoff	1998	MicroVisc Plus	-	-0.77 (-1.07, -0.46)	24.67
Arshinoff	1998	Healon GV		-0.80 (-1.11, -0.49)	24.53
Espindola	2012	DisCoVisc	-++-	-0.58 (-1.03, -0.13)	11.26
Espindola	2012	2% HPMC	-	-0.45 (-0.90, -0.00)	11.45
I - V subtotal (<i>I</i> -squared = 0.0%, $p = 0.828$)			\diamond	-0.72 (-0.87, -0.56)	100.00
D + L subtot	al	*	ò	-0.72 (-0.87, -0.56)	
			-2.57 0	2.57	

FIGURE 14: Forest plot for studies examining pre- and postoperative intraocular pressure (IOP) by three- and six-month follow-up.

Author	Year of publication	OVD	SMD (95% CI)	% weigh (I - V)
1 day follow-up				
Davis	2000	Amvisc Plus —	-1.10 (-1.83, -0.38)	5.56
Davis	2000	OcuCoat —	-0.80 (-1.50, -0.10)	5.95
Davis	2000	Viscoat —	-0.90 (-1.63, -0.17)	5.49
Lee	2011	Amvisc Plus	-0.62 (-1.13, -0.11)	11.23
Lee	2011	Balanced salt solution	-0.53 (-1.04, -0.03)	11.37
Miyata	2002b	Soft shell —	-1.90 (-2.45, -1.35)	9.61
Miyata	2002b	Healon —	-1.70 (-2.38, -1.02)	6.35
Shingleton	2001	Vitrax•	-0.22 (-0.70, 0.27)	12.47
Shingleton	2001	Anterior chamber maintainer	-0.23 (-0.72, 0.25)	12.46
Vajpayee	2005	Viscoat	-0.62 (-1.27, 0.03)	6.87
Vajpayee	2005	Healon GV —	-1.01 (-1.69, -0.33)	6.36
Vajpayee	2005	Healon5 —	-0.82 (-1.51, -0.14)	6.28
I - V subtotal (<i>I</i> -squared = 69.3%, $p = 0.000$)			-0.79 (-0.97, -0.62)	100.00
D + L subtotal	1 1	, Š	-0.85 (-1.16, -0.54)	
2 days follow-up				
Yachimori	2004	Opegan	-0.80 (-1.29, -0.31)	49.39
Yachimori	2004	Soft shell	-0.82 (-1.31, -0.31)	50.61
<i>I</i> - <i>V</i> subtotal (<i>I</i> -squared = 0.0%, <i>p</i> = 0.945)			-0.81 (-1.16, -0.46)	100.00
D + L subtotal		\diamond	-0.81 (-1.16, -0.46)	
3 days follow-up		_		
Moschos	2011	Viscoat —	-0.78 (-1.23, -0.33)	52.08
Moschos	2011	Visthesia	-0.48 (-0.94, -0.01)	47.92
I - V Subtotal (I-s	quared = 0.0%, <i>p</i>	= 0.354)	-0.63 (-0.96, -0.31)	100.00
D + L Subtotal		\diamond	-0.63 (-0.96, -0.31)	
1 week follow-up		_		
Miyata	2002b	Soft shell	-2.10 (-2.67, -1.53)	60.18
Miyata	2002b	Healon	-1.90 (-2.60, -1.20)	39.82
I - V subtotal (I-s	quared = 0.0%, <i>p</i>	= 0.665)	-2.02 (-2.46, -1.58)	100.00
D + L subtotal		\diamond	-2.02 (-2.46, -1.58)	
2 week follow-up		_		
Moschos	2011	Viscoat	-2.08 (-2.62, -1.54)	52.07
Moschos	2011	Visthesia	-1.94 (-2.50, -1.38)	47.93
I - V subtotal (I -squared = 0.0%, $p = 0.720$)			-2.01 (-2.40, -1.62)	100.00
D + L subtotal		\diamond	-2.01 (-2.40, -1.62)	
		-2.67		

FIGURE 15: Forest plot for studies examining pre- and postoperative best corrected visual acuity (BCVA) by follow-up (days).

perform cataract surgery, rates of complications, and years when the surgeries were performed, as well as years when the studies were conducted. The results imply that good quality studies with longer follow-up periods need to be reported to better understand the optimal role of various OVDs in IOP management.

The limitations for systematic reviews and meta-analyses such as this one are necessary before conclusions are made. Firstly, included articles were of high, medium, and poor quality. However, few studies evaluating each OVD were available for analysis; all were included, irrespective of their quality. This is a recognized, but necessary, limitation due to the few clinical studies currently available examining each OVD. Secondly, meta-analysis of observational studies is influenced by inherent biases in the included articles [41]. For example, a multitude of other factors such as level of education, ethnicity, income status, socioeconomic status, previous ocular and nonocular surgeries, family history, other ocular and nonocular diseases, preoperative and postoperative medications, number of medications, and comorbidities (e.g., high blood pressure, diabetes, stroke, heart conditions, etc.) could influence the estimates in the original studies.

Our analysis indicated improvement in IOP with Viscoat + Provisc in 24-hour follow-up. Additionally, IOP nonsignificant upsurge was observed with Healon GV, Healon5, 2% HPMC, and OcuCoat compared to significant upsurge with Healon, Viscoat, and Soft Shell in 24-hour follow-up. The reason for this could be careful removal of OVD after cataract surgery. Therefore, it is not possible to

Author	Year of publication	OVD	SMD (95% CI)	% weigh (I - V)
1 month follow-u	ıp			
Arshinoff	1997	MicroVisc	-4.92 (-5.76, -4.08)	3.53
Arshinoff	1997	Healon	-7.30 (-8.43, -6.17)	1.94
Arshinoff	1998	MicroVisc Plus	◆ -1.48 (-1.79, -1.17)	25.18
Arshinoff	1998	Healon GV	◆ -1.48 (-1.79, -1.17)	25.18
Lee	2011	OcuCoat	◆ -0.92 (-1.45, -0.40)	8.98
Lee	2011	Balanced Salt Solution	◆ -0.86 (-1.38, -0.34)	9.09
Miyata	2002b	Soft Shell	◆ -2.18 (-2.76, -1.60)	7.38
Miyata	2002b	Healon	-1.90 (-2.60, -1.20)	5.02
Moschos	2011	Viscoat	-2.69 (-3.29, -2.09)	6.84
Moschos	2011	Visthesia	◆ -2.31 (-2.91, -1.71)	6.86
- V subtotal (I-s	quared = 95.2% , p =	= 0.000)	♦ -1.82 (-1.98, -1.66)	100.00
D + L subtotal	quarea yei270, p		 ↓ ↓	100100
6 weeks follow-u	р			
Shingleton	2001	Vitrax	◆ -0.29 (-0.77, 0.20)	50.16
Shingleton	2001	Anterior chamber maintainer	← -0.36 (-0.85, 0.12)	49.84
0	quared = 0.0% , $p =$	0.830)	→ -0.33 (-0.67, 0.02)	100.00
D + L subtotal	1	·····,	-0.33 (-0.67, 0.02)	
3 months follow-	up			
Lee	2011	Viscoat	◆ -0.93 (-1.46, -0.41)	17.53
Lee	2011	Balanced Salt Solution	◆ -0.74 (-1.26, -0.23)	18.20
Miyata	2002b	Soft Shell	◆ -2.18 (-2.76, -0.60)	14.45
Miyata	2002b	Healon	→ -1.90 (-2.60, -1.20)	9.83
Yachimori	2004	Opegan	◆ -0.80 (-1.29, -0.31)	19.75
Yachimori	2004	Soft shell	◆ -0.82 (-1.31, -0.34)	20.24
- V subtotal (I-s	quared = 78.5% , p =	= 0.000)	↓ -1.12 (-1.34, -0.91)	100.00
D + L subtotal	1		-1.20 (-1.68, -0.72)	
6 months follow-	up			
Arshinoff	1997	MicroVisc	◆ -4.60 (-5.40, -3.80)	5.22
Arshinoff	1997	Healon	-7.54 (-8.70, -6.38)	2.45
Arshinoff	1998	MicroVisc Plus	◆ -1.35 (-1.66, -1.04)	34.96
Arshinoff	1998	Healon GV	◆ -1.35 (-1.66, -1.04)	34.96
Vajpayee	2005	Viscoat	◆ -0.88 (-1.54, -0.21)	7.42
Vajpayee	2005	Healon GV	◆ -0.30 (-0.94, 0.34)	8.07
Vajpayee	2005	Healon5	◆ -0.94 (-1.63, -0.25)	6.93
	quared = 96.7%, <i>p</i> =	= 0.000)	♦ -1.52 (-1.70, -1.34)	100.00
D + L subtotal		,	-2.33 (-3.43, -1.23)	

FIGURE 16: Forest plot for studies examining pre- and postoperative best corrected visual acuity (BCVA) follow-up (months).

differentiate OVD in increasing IOP. Further, additional research is needed to better understand how to maximize the utility of OVD in cataract management.

In conclusion, results indicated that postoperative IOP does significantly increase irrespective of OVD up to 5 hours of follow-up. Therefore, careful removal of OVD is essential to avoid the IOP spikes. More good quality RCTs are needed to better understand and define the position of OVDs in cataract management.

Data Availability

The data used to support the findings of the study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors' Contributions

Malvankar-Mehta and Hutnik contributed to study concept and design; participated in administrative, technical, or material support; and supervised the study. Fu and Subramanian were responsible for data acquisition. Malvankar-Mehta drafted the manuscript, carried out data analysis and interpretation, and takes responsibility for the integrity of data and the accuracy of data analysis. Malvankar-Mehta, Fu, Subramanian, and Hutnik critically revised the manuscript for important intellectual content.

Supplementary Materials

S1: PRISMA 2009 checklist. S2: search strategy for EMBASE and MEDLINE. S3: Levels 1, 2, and 3 screening questions. S4: Funnel plots. S5: Intraocular pressure (IOP) reported in studies included in the meta-analysis. (*Supplementary Materials*)

References

- M. P. Holzer, M. R. Tetz, G. U. Auffarth, R. Welt, and H.-E. Völcker, "Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery," *Journal of Cataract & Refractive Surgery*, vol. 27, no. 2, pp. 213–218, 2001.
- [2] E. A. Davis and R. L. Lindstrom, "Corneal thickness and visual acuity after phacoemulsification with 3 viscoelastic materials," *Journal of Cataract & Refractive Surgery*, vol. 26, no. 10, pp. 1505–1509, 2000.
- [3] S. A. Arshinoff, D. A. Albiani, and J. Taylor-Laporte, "Intraocular pressure after bilateral cataract surgery using Healon, Healon5, and Healon GV," *Journal of Cataract & Refractive Surgery*, vol. 28, no. 4, pp. 617–625, 2002.
- [4] S. A. Arshinoff and I. Hofman, "Prospective, randomized trial comparing MicroVisc Plus and Healon GV in routine phacoemulsification," *Journal of Cataract & Refractive Sur*gery, vol. 24, no. 6, pp. 814–820, 1998.
- [5] K. M. Miller and M. D. Colvard, "Randomized clinical comparison of Healon GV and Viscoat1," *Journal of Cataract* & *Refractive Surgery*, vol. 25, no. 12, pp. 1630–1636, 1999.
- [6] T. Oshika, H. Bissen-Miyajima, Y. Fujita et al., "Prospective randomized comparison of DisCoVisc and Healon5 in phacoemulsification and intraocular lens implantation," *Eye*, vol. 24, no. 8, pp. 1376–1381, 2010.
- [7] G. Rainer, R. Menapace, O. Findl, M. Georgopoulos, B. Kiss, and V. Petternel, "Intraocular pressure after small incision cataract surgery with Healon5 and Viscoat," *Journal of Cataract & Refractive Surgery*, vol. 26, no. 2, pp. 271–276, 2000.
- [8] G. Rainer, R. Menapace, O. Findl et al., "Intraocular pressure rise after small incision cataract surgery: a randomised intraindividual comparison of two dispersive viscoelastic agents," *British Journal of Ophthalmology*, vol. 85, no. 2, pp. 139–142, 2001.
- [9] G. Rainer, R. Menapace, K. E. Schmid et al., "Natural course of intraocular pressure after cataract surgery with sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat)," *Ophthalmology*, vol. 112, no. 10, pp. 1714–1718, 2005.
- [10] G. Rainer, K. E. Schmid, O. Findl et al., "Natural course of intraocular pressure after cataract surgery with sodium hyaluronate 1% versus hydroxypropylmethylcellulose 2%," *Ophthalmology*, vol. 114, no. 6, pp. 1089–1093, 2007.
- [11] S. A. Arshinoff and I. Hofmann, "Prospective, randomized trial of Microvisc and Healon in routine phacoemulsification," *Journal of Cataract & Refractive Surgery*, vol. 23, no. 5, pp. 761–765, 1997.
- [12] T. Kohnen, M. von Ehr, E. Schütte, and D. D. Koch, "Evaluation of intraocular pressure with Healon and Healon GV in sutureless cataract surgery with foldable lens implantation," *Journal of Cataract & Refractive Surgery*, vol. 22, no. 2, pp. 227–237, 1996.

- [13] M. M. Moschos, I. P. Chatziralli, and T. N. Sergentanis, "Viscoat versus Visthesia during phacoemulsification cataract surgery: corneal and foveal changes," *BMC Ophthalmology*, vol. 11, no. 1, p. 9, 2011.
- [14] A. Van den Bruel, J. Gailly, S. Devriese, N. J. Welton, A. J. Shortt, and F. Vrijens, "The protective effect of ophthalmic viscoelastic devices on endothelial cell loss during cataract surgery: a meta-analysis using mixed treatment comparisons," *British Journal of Ophthalmology*, vol. 95, no. 1, pp. 5–10, 2011.
- [15] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and P. G. The, "Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement," *PLoS Medicine*, vol. 6, no. 7, Article ID e1000097, 2009.
- [16] S. H. Downs and N. Black, "The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions," *Journal of Epidemiology & Community Health*, vol. 52, no. 6, pp. 377–384, 1998.
- [17] W. Y. Zhang, A. L. W. Po, H. Dua, and A. Azuara-Blanco, "Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension," *British Journal* of Ophthalmology, vol. 85, no. 8, pp. 983–990, 2001.
- [18] G. U. Auffarth, F. N. Auerbach, T. Rabsilber et al., "Comparison of the performance and safety of 2 ophthalmic viscosurgical devices in cataract surgery," *Journal of Cataract & Refractive Surgery*, vol. 43, no. 1, pp. 87–94, 2017.
- [19] A. Behndig and B. Lundberg, "Transient corneal edema after phacoemulsification: comparison of 3 viscoelastic regimens," *Journal of Cataract & Refractive Surgery*, vol. 28, no. 9, pp. 1551–1556, 2002.
- [20] D. Chiselita, C. Danielescu, and D. Gherghel, "Intraocular pressure after cataract surgery using Provasc, Viscoat either separately or in combination," *Oftalmologia (Bucharest, Romania: 1990)*, vol. 52, no. 3, pp. 91–97, 2008.
- [21] P. J. Embriano, "Postoperative pressures after phacoemulsification: sodium hyaluronate vs. sodium chondroitin sulfatesodium hyaluronate," *Annals of Ophthalmology*, vol. 21, no. 3, pp. 85–90, 1989.
- [22] R. F. Espíndola, E. F. Castro, M. R. Santhiago, and N. Kara-Junior, "A clinical comparison between DisCoVisc and 2% hydroxypropylmethylcellulose in phacoemulsification: a fellow eye study," *Clinics (Sao Paulo, Brazil)*, vol. 67, no. 9, pp. 1059–1062, 2012.
- [23] W. W. Hütz, B. H. Eckhardt, and T. Kohnen, "Comparison of viscoelastic substances used in phacoemulsification," *Journal* of Cataract & Refractive Surgery, vol. 22, no. 7, pp. 955–959, 1996.
- [24] H. Kim and C.-K. Joo, "Efficacy of the soft-shell technique using Viscoat and Hyal-2000," *Journal of Cataract & Refractive Surgery*, vol. 30, no. 11, pp. 2366–2370, 2004.
- [25] A. Koçak-Altintas, M. Anayol, H. Cakmak, and S. Simsek, "Effects of topical dorzolamide on IOP after phacoemulsification with different types of ophthalmic viscosurgical devices," *European Journal of Ophthalmology*, vol. 17, no. 1, pp. 38–44, 2006.
- [26] H. Y. Lee, Y. J. Choy, and J. S. Park, "Comparison of OVD and BSS for maintaining the anterior chamber during IOL implantation," *Korean Journal of Ophthalmology*, vol. 25, no. 1, pp. 15–21, 2011.
- [27] K. Miyata, S. Maruoka, M. Nakahara et al., "Corneal endothelial cell protection during phacoemulsification: low-versus high-molecular-weight sodium hyaluronate," *Journal of*

Cataract & Refractive Surgery, vol. 28, no. 9, pp. 1557–1560, 2002.

- [28] K. Miyata, T. Nagamoto, S. Maruoka, T. Tanabe, M. Nakahara, and S. Amano, "Efficacy and safety of the softshell technique in cases with a hard lens nucleus," *Journal of Cataract & Refractive Surgery*, vol. 28, no. 9, pp. 1546–1550, 2002.
- [29] T. Neumayer, A. Prinz, and O. Findl, "Effect of a new cohesive ophthalmic viscosurgical device on corneal protection and intraocular pressure in small-incision cataract surgery," *Journal of Cataract & Refractive Surgery*, vol. 34, no. 8, pp. 1362–1366, 2008.
- [30] T. Oshika, S. Eguchi, K. Oki et al., "Clinical comparison of Healon5 and Healon in phacoemulsification and intraocular lens implantation: randomized multicenter study," *Journal of Cataract & Refractive Surgery*, vol. 30, no. 2, pp. 357–362, 2004.
- [31] N. Ray-Chaudhuri, G. M. Voros, S. Sutherland, and F. C. Figueiredo, "Comparison of the effect of sodium hyaluronate (ophthalin) and hydroxypropylmethylcellulose (HPMC-Ophtal) on corneal endothelium, central corneal thickness, and intraocular pressure after phacoemulsification," *European Journal of Ophthalmology*, vol. 16, no. 2, pp. 239–246, 2005.
- [32] G. Rainer, E. Stifter, A. Luksch, and R. Menapace, "Comparison of the effect of Viscoat and DuoVisc on postoperative intraocular pressure after small-incision cataract surgery," *Journal of Cataract & Refractive Surgery*, vol. 34, no. 2, pp. 253–257, 2008.
- [33] G. Ravalico, D. Tognetto, F. Baccara, and A. Lovisato, "Corneal endothelial protection by different viscoelastics during phacoemulsification," *Journal of Cataract & Refractive Surgery*, vol. 23, no. 3, pp. 433–439, 1997.
- [34] O. Schwenn, H. B. Dick, F. Krummenauer, S. Christmann, A. Vogel, and N. Pfeiffer, "Healon5 versus Viscoat during cataract surgery: intraocular pressure, laser flare and corneal changes," *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 238, no. 10, pp. 861–867, 2000.
- [35] Z. Stanković and S. Paunović, "Influence of viscoelastics on eye pressure changes following the cataract surgery," *Serbian Journal of Experimental and Clinical Research*, vol. 9, no. 2, pp. 49–51, 2008.
- [36] A. Storr-Paulsen, J. C. Nørregaard, G. Farik, and J. Tårnhøj, "The influence of viscoelastic substances on the corneal endothelial cell population during cataract surgery: a prospective study of cohesive and dispersive viscoelastics," *Acta Ophthalmologica Scandinavica*, vol. 85, no. 2, pp. 183–187, 2007.
- [37] J. Strobel, "Comparison of space-maintaining capabilities of Healon and Healon GV during phacoemulsification," *Journal* of Cataract & Refractive Surgery, vol. 23, no. 7, pp. 1081–1084, 1997.
- [38] B. Thirumalai, T. L. Blamires, L. Brooker, and J. Deeks, "Heavier molecular weight ocular viscoelastic devices and timing of post-operative review following cataract surgery," *BMC Ophthalmology*, vol. 7, no. 1, p. 2, 2007.
- [39] R. B. Vajpayee, K. Verma, R. Sinha, J. S. Titiyal, R. M. Pandey, and N. Sharma, "Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsification [ISRCTN34957881]," *BMC Ophthalmology*, vol. 5, no. 1, p. 17, 2005.
- [40] R. Yachimori, T. Matsuura, K. Hayashi, and H. Hayashi, "Increased intraocular pressure and corneal endothelial cell loss following phacoemulsification surgery," *Ophthalmic*

Surgery, Lasers and Imaging Retina, vol. 35, no. 6, pp. 453–459, 2004.

[41] M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test," *The British Medical Journal*, vol. 315, no. 7109, pp. 629–634, 1997.